Hosted on MSN27d
Eli Lilly in pact with Magnet Bio to develop cancer drugs in a deal worth up to $1.25B
Magnet Biomedicine announced Friday it has reached a licensing agreement worth up to $1.25B with Eli Lilly (NYSE:LLY) to develop cancer drugs leveraging the company’s TrueGlue discovery platform.
Daily Excelsior2d
Eli Lilly Global CEO meets Dr Jitendra; discusses Insulin, NCD drugs collaboration
Global CEO of Eli Lilly, world’s pioneer Insulin manufacturers, David Ricks called on Union Minister of State (Independent ...